Clinical Trials Logo

Cervical Cancer Recurrent clinical trials

View clinical trials related to Cervical Cancer Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT06455046 Recruiting - Clinical trials for Cervical Cancer Recurrent

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Start date: October 11, 2023
Phase: Phase 2
Study type: Interventional

In order to improve the clinical effect and find a new safe and effective treatment model for advanced recurrent cervical cancer, this study explored the efficacy level safety of pemetrexed, carboplatin, recombinant human adenovirus type 5, and AK104 regimen in recurrent and refractory advanced cervical cancer. For some patients with immune-resistant cervical cancer, combination chemotherapy and oncolytic virus therapy can promote the transformation of cold tumors into hot tumors, eliminate and then reverse the suppressor factors of immune resistance, and break the dilemma of immunotherapy drug resistance, which is a new method and strategy under immunotherapy drug resistance.

NCT ID: NCT06063018 Recruiting - Clinical trials for Cervical Cancer Recurrent

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Start date: August 16, 2023
Phase: Phase 2
Study type: Interventional

There is currently no standardized treatment for patients who have undergone first-line standard treatment. In this study, We investigated the efficacy and safty of RC48 combined with Tislelizumab in the second-line treatment of patients with HER2 expression in recurrent cervical cancer.

NCT ID: NCT03912402 Recruiting - Cervical Cancer Clinical Trials

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Start date: December 25, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with recurrent/persistent or metastatic cervical cancer.

NCT ID: NCT03614949 Recruiting - Cervical Cancer Clinical Trials

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Start date: January 29, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent, persistent, or metastatic cervical cancer.